Metys Pharmaceuticals is now part of Novaremed!
On September 7, 2021, Novaremed AG, a privately held clinical-stage biopharmaceutical company, announced the acquisition of Metys Pharmaceuticals AG, including all of its development programs, in an all-share transaction. The acquisition broadens Novaremed’s existing pipeline by adding both clinical and preclinical development projects based on an innovative approach for non-opioid chronic pain treatment, the Company’s focus area. Moreover, it enables Novaremed to target a wider spectrum of neuropathic pain indications, potentially also addressing broader applications by including prevention in addition to the treatment of pain.
Please visit www.novaremed.com to read the full press release and access additional information.